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Heparan sulfate proteoglycans (HSPGs) are an integral and dynamic part of normal tis-
sue architecture at the cell surface and within the extracellular matrix. The modification of
HSPGs in the tumor microenvironment is known to result not just in structural but also
functional consequences, which significantly impact cancer progression. As substrates
for the key enzymes sulfatases and heparanase, the modification of HSPGs is typically
characterized by the degradation of heparan sulfate (HS) chains/sulfation patterns via the
endo-6-O-sulfatases (Sulf1 and Sulf2) or by heparanase, an endo-glycosidase that cleaves
the HS polymers releasing smaller fragments from HSPG complexes. Numerous studies
have demonstrated how these enzymes actively influence cancer cell proliferation, sig-
naling, invasion, and metastasis. The activity or expression of these enzymes has been
reported to be modified in a variety of cancers. Such observations are consistent with the
degradation of normal architecture and basement membranes, which are typically com-
promised in metastatic disease. Moreover, recent studies elucidating the requirements
for these proteins in tumor initiation and progression exemplify their importance in the
development and progression of cancer. Thus, as the influence of the tumor microenvi-
ronment in cancer progression becomes more apparent, the focus on targeting enzymes
that degrade HSPGs highlights one approach to maintain normal tissue architecture, inhibit
tumor progression, and block metastasis.This review discusses the role of these enzymes
in the context of the tumor microenvironment and their promise as therapeutic targets for
the treatment of cancer.
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INTRODUCTION
Heparan sulfate (HS) chains are an important component of the
extracellular matrix (ECM) and they facilitate a number of impor-
tant biological processes in health and disease. Incorporated into
heparan sulfate proteoglycans (HSPG), they comprise a signifi-
cant fraction of the complex and dynamic ECM and contribute
to the biological roles of this medium. The functions of HSPG
are varied: the maintenance of a 3D structural matrix for cell
attachment; in certain cases the formation of barrier structures
(basement membranes); the provision of a reservoir of biological
signaling molecules; acting as a cofactor for signaling molecules
binding to their receptors (1–3). These functions are modulated
by proteins that are released into the ECM to modify its con-
stituent molecules. Three important proteins within this category
are heparanase (4–6), Sulf1, and Sulf2 (7, 8), which are released by
a variety of cells to modify the structure of HS and thereby alter
the function of the ECM.
This review will focus upon the roles of these three enzymes
in modifying HS in the tumor microenvironment to facilitate
processes that support or repress cancer growth and spread. The
importance of heparanase, Sulf1, and Sulf2 will also be demon-
strated by exploring their association with poor patient prognosis
in clinical studies. Finally, the relevant therapeutic developments
in the area will be summarized.
ENZYME PROPERTIES
HEPARANASE
There is only one heparanase gene known in mammals (HPSE in
humans) and it expresses a 65 kDa precursor polypeptide that is
enzymatically inactive. Proteolytic excision by cathepsin L of a 48
amino acid peptide yields an active heterodimer comprising 8 and
50 kDa subunits. Although the structures of precursor and active
heparanase are unknown, it has been postulated that the excised
linker sequence occludes the active site based on sequence analysis
and that once removed the active site is revealed allowing catalysis
to proceed (9). Sequence homology modeling has indicated that
heparanase contains a TIM barrel fold, which incorporates the
two HS-binding regions (residues 158–162 and 270–280) and the
catalytic residues (Glu225 and Glu343) of the active site (10–14).
The C terminus of the protein forms a discrete domain, which
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FIGURE 1 | Mechanisms whereby heparanase, Sulf1, and Sulf2 regulate
HS function to promote or inhibit tumor growth and spread. (A) HS
modification by these three enzymes can have promoting or inhibiting effects
on growth factor (GF) signaling. (B) Heparanase, in association with
sheddases, can stimulate HSPG shedding, dispersing autocrine to paracrine
signaling. (C) Heparanase and Sulf2 can up-regulate HSPG expression to
promote GF signaling. And (D) heparanase can induce exosome secretion
allowing tumor cell communication with neighboring cells.
has non-catalytic properties and is involved in a heparanase-
mediated signaling function that is distinct from its enzymatic
activity (15, 16). This review will focus upon the enzymatic
activity of heparanase and its role in regulating HS functioning
in the ECM.
Catalytically, heparanase is an endo-β glucuronidase that
cleaves HS chains at a limited number of sites within HS chains
yielding relatively large degradation fragments [5–10 kDa or 10–20
sugar units (17)]. The exact substrate requirements for heparanase
have not been clarified and recent studies suggest that it has alter-
nating modes of catalysis (18), but it appears to favor trisaccha-
ride sequences containing flanking glucosamine residues that are
N - and 6-O sulfated (19). The pH optimum for heparanase catal-
ysis peaks at 5 and the enzyme possesses little activity above 7 (20).
SULF1 AND SULF2
Sulf1 and Sulf2 are two closely related members of the sulfatase
family (human genes SULF1 and SULF2). Unlike most other sul-
fatases, which are intracellular and function in the catabolism of
sulfated molecules, Sulf1 and Sulf2 are extracellularly targeted
and function by selectively removing 6-O-sulfate groups from
glucosamine residues within HS polymers. Like heparanase, the
Sulfs are also expressed as precursor polypeptides (125 kDa) and
are processed by a furin-type protease to produce the mature
heterodimer comprising 75 and 50 kDa subunits connected by
disulfide linkages (21, 22). Although the active site is contained
in the 75 kDa subunit, both subunits are required for activity. In
contrast to heparanase, the pH optima for the Sulfs are 7–8 (23).
Significantly, catalysis by either Sulf to remove 6-O-sulfates from
HS chains would reduce the affinity that heparanase has for these
portions of the glycosaminoglycan. It is not clear,however,whether
the Sulfs play a role in modulating heparanase activity and, thus,
regulating its function in vivo.
MOLECULAR PROCESSES IN TUMOR MICROENVIRONMENT
Heparanase, Sulf1, and Sulf2 have been shown, by virtue of
their enzymatic modification of the ECM, to affect the signal-
ing of a number of proteins that are important drivers of tumor
growth or progression. In some instances, the signaling function
of heparanase may be involved in driving these changes, but it is
accepted that heparanase cleavage of HS also plays a significant role
in modulating signal transduction. These three enzymes accom-
plish this modulation in signaling in a number of ways (Figure 1).
Firstly, heparanase and Sulf activity modifies the HS component
of the ECM, thus altering the interactions between signaling mole-
cules and their receptors. Secondly, heparanase is closely linked to
the process of syndecan shedding, particularly syndecan-1, which
can be important in changing the focus of a signaling stimu-
lus, for example from autocrine to paracrine. Thirdly, heparanase
and Sulf2 regulate expression of HSPG at the cell surface, thus
promoting HS-dependant signaling. And fourthly, heparanase is
involved in exosome formation by cancer cells, which has recently
been shown to promote tumor progression by acting upon both
cancerous and stromal cells.
HS MODIFICATION TO MODULATE SIGNALING
The modification of HS chains in the ECM to liberate stored signal-
ing molecules in the tumor microenvironment is a mechanism that
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heparanase and the sulfatases have in common. There is, however,
some diversity in the outcomes resulting from the modification of
HS by these three enzymes. Heparanase cleavage of HS has been
shown to increase the solubility of a variety of signaling molecules
includingVEGF (24) and FGF2 (25, 26) thus increasing their access
to receptors and facilitating signal transduction. This property has
linked heparanase with the promotion of a number of pro-tumor
processes including angiogenesis, cell proliferation and invasion,
inhibition of apoptosis, and metastasis.
In addition to its catalysis resulting in increased availability
of signaling molecules, heparanase cleavage of HSPG can also
facilitate the interaction of these molecules with their receptors.
Moderate heparanase activity has been shown to potentiate FGF2
signaling (27). This effect appears to be due to the solubilization
of HS chains by heparanase as demonstrated by the observation
that heparanase-cleaved HS chains stimulated FGF2 activity in
the absence of heparanase itself. Soluble HS may improve the
likelihood of formation of the active FGF2–FGFR–HS ternary
complex by easing the conformational constraints of this assembly.
A contrasting mechanism was discovered with lacritin in which
heparanase promotes the activity of this mitogenic protein by
removing the HS chains from syndecan-1 leaving the deglycanated
HSPG as the active receptor for lacritin (28).
Rather than having uniformly tumor-promoting properties,
Sulf1 and Sulf2 have pro- and anti-tumor affects. Functionally,
activity of both sulfatases is linked to angiogenesis, albeit in oppos-
ing manner. Despite their similar enzymatic activities, evidence
suggests that Sulf1 and Sulf2 play opposing roles in the progression
of tumors. For example, Sulf1 has been shown to attenuate the sig-
naling of HS-binding growth factors such as FGF2 (29, 30), VEGF
(30), amphiregulin (31), HB-EGF (29), and HGF (32, 33). Such
effects are mediated by reduced affinity of these signaling proteins
for vascular endothelial HS, thus reducing their concentration at
the cell surface and minimizing interaction with their cognate
receptors. Perhaps, the most studied example is the attenuation
of FGF2 signaling by Sulf1. The removal of 6-O-sulfate groups
by Sulf1 reduces formation of the active ternary FGF2–FGFR–
HS complex and consequently blocks FGF2 signaling (34, 35).
However, the regulatory functions of Sulf1 have added complex-
ity because alternative splicing of this gene can generate isoforms,
which have different effects on Wnt signaling (36).
In contrast to Sulf1, Sulf2 has been shown to mobilize and
increase the signaling of FGF2 in HCC cells (37). Interestingly,
it accomplishes this despite having the same 6-O-endosulfatase
activity as Sulf1 and despite the observed FGF2 signaling remain-
ing HS dependant (37). Sulf2 has shown similar promotion of
signaling with several other HS-binding signaling proteins includ-
ing VEGF (38), Wnt (39, 40), SDF1 (38), and GDNF (41). Apart
from the opposing roles played by Sulf1 and Sulf2 in regulating
tumor growth through mobilizing heparan binding growth fac-
tors, these endosulfatases are also involved in regulating apoptotic
proteins enhancing the sensitivity to chemotherapeutic agents in
ovarian cancer. Recently, it was shown that Sulf1 depletion in
ovarian cancer cells resulted in marked decrease in pro-apoptotic
protein such as Bim, thus promoting tumor growth (42). Although
reduction in Bim levels were attributed to high ERK activities, it
underscores the possibility that lower levels of apoptotic proteins
will favor resistance to chemotherapeutic agents. Along these lines,
it was demonstrated that genetic silencing of Sulf1 in ovarian
cancer cells attenuated cisplatin induced cytotoxicity (43). Con-
sistent with their opposing roles in growth factor signaling, Sulf2
expression attenuated cell death induction by MEK, JNK, and PI3K
inhibitors in hepatocellular carcinoma cell lines. These data were
further strengthened by the finding that Sulf2 expression levels
were elevated in human hepatocellular carcinoma (44). Overall,
it is conceivable to conclude that Sulf1 plays anti-tumor roles
whereas Sulf2 plays tumor-promoting roles in several tumor types.
The paradox of how two sulfatases with similar catalytic activities
have different biological functions and outcomes in tumor types,
remains to be solved.
SYNDECAN SHEDDING
The expression and mobilization of HSPG, such as syndecan,
in the tumor and stroma microenvironment is associated with
poor prognosis in a number of cancers. Expressed at the cell sur-
face, these proteoglycans can be shed by the action of proteases
referred to as sheddases. The protein core of the syndecan HSPG
is cleaved by proteases, such as MMP-9, releasing it from attach-
ment to the cell membrane. Although sheddases are responsible
for releasing syndecan from the cell surface, heparanase promotes
this process in two ways: firstly, by degrading HS chains, it increases
the rate at which sheddases cleave the core protein (45) and sec-
ondly, heparanase can increase the expression of sheddases such
as MMP-9 (46). Shed syndecan, because it commonly contains
bound signaling proteins, facilitates the translocation of these sig-
nals from the expressing cell, which may be a tumor cell, to stromal
cells, thus converting autocrine signaling into a paracrine signal
(47–49). It is noteworthy that shed syndecan ectodomain, which
can be detected in sampled plasma or serum, represents a poten-
tial biomarker for the malignancy status of cancer (50) and its
response to a heparanase-targeting therapeutic.
HS UPREGULATION
Both heparanase and Sulf2 are capable of increasing expression
of HSPG targeted to the cell surface and, consequently, increas-
ing pro-tumor signaling by HS-binding growth factors. Sulf2 has
been shown to activate the Wnt pathway via upregulating glyp-
ican 3 at the cell surface, which results in enhanced Wnt–Frz
complex formation and increased Wnt-β-catenin signaling (37,
39, 51). Similarly, heparanase has been demonstrated to regu-
late the expression of syndecan-1 in multiple myeloma cells (52).
Heparanase promotes the expression of this cell surface HSPG,
which is involved in facilitating the transduction of a range of sig-
naling pathways including FGF2 (53), Wnt (54), and HGF (55).
Apart from exerting control over the total mass of HS, there is evi-
dence to suggest that heparanase also affects the composition of
the HS chains. Higher levels of heparanase expression correlated
with increased N - and O-sulfation of HS chains which lead to
potentiation of FGF1 and FGF2 signaling (56).
EXOSOME SECRETION
Another mechanism, recently discovered, by which heparanase is
able to promote tumor malignancy is via the stimulation of exo-
some secretion (57), although as yet Sulf1 and Sulf2 have not been
shown to be involved in this process. Exosomes are lipid membrane
bound extracellular vesicles that allow tumor cells to communicate
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with and co-opt neighboring cells to assist in modifying the tumor
microenvironment and, thus, promote the tumor’s growth and
spread (58–60). Heparanase enzymatic activity has been shown
to promote the formation of exosomes by several types of cancer
cells and, moreover, to affect the molecular composition of the
exosomes (57). The resulting exosomes were potent stimulators of
both tumor and endothelial cells (Figure 1). The significance of
this process in cancer has yet to be established but, if confirmed,
would highlight the diversity of heparanase functions in tumor
promotion.
POTENT REGULATORS OF HS FUNCTION
Heparanase, Sulf1, and Sulf2 drive a range of processes in
the tumor microenvironment, many of which, in the case of
heparanase and Sulf2 promote tumor malignancy, and some, in
the case of Sulf1 inhibit malignancy. Despite their shared sub-
strate and significance in cancer progression, it is important to
note that the pH optima of heparanase (pH 5) and the Sulfs
(pH 7–8) preclude them from being at their most active in the
same microenvironment compartment, or at the same time. The
low extracellular pH associated with tumor-driven hypoxia has
the consequence of stimulating heparanase-mediated activation
of pro-angiogenic growth factors leading to a replenishment of
the tumor microenvironment (61–63). Interestingly, Sulf1 and
Sulf2 show the opposite environmental regulation being sup-
pressed during hypoxia (64, 65). This is unsurprising for Sulf1,
given its largely antagonistic function compared to heparanase.
Sulf2, however, has pro-angiogenic properties like heparanase but
is, nonetheless, downregulated under conditions requiring new
blood supply. This apparent paradox suggests a complicated reg-
ulatory interaction between heparanase and the Sulfs. One could
speculate that the Sulfs, with their neutral pH optimum and fine
interplay between pro- and anti-angiogenic functions, are the
early regulators of HS remodeling to control angiogenesis but, if
metabolic changes or tumor growth drive the compartment into
hypoxia, then heparanase becomes the leading regulator.
CELLULAR PROCESSES
For some time, the involvement of heparanase in the metastatic
extravasation of tumor cells and invasion of immune cells has been
known. We will not cover in detail the work describing the impor-
tance of heparanase in these processes but will instead refer the
interested reader to the excellent reviews that have already sum-
marized this data (5, 6, 66). Rather, we will highlight one of the
areas of research that has recently increased our understanding
of heparanase functioning at the cellular level: namely its role in
promoting epithelial–mesenchymal transition (EMT).
The transition of epithelial cells from their polarized state
to non-polarized multipotent mesenchymal cells is an impor-
tant process during metastasis. Recent studies examining EMT
of kidney tubule epithelial cells into myofibroblasts show that
heparanase is involved in driving this process by promoting FGF2
signaling (67). The mechanism whereby heparanase promotes this
activity is not clear but it appears to involve enzymatic activity
because the heparanase inhibitor sulodexide abrogates the effect
(68). While these results were obtained using kidney tubule cells,
it is intriguing to speculate that the heparanase-FGF2 axis plays
an important role in cancer spread due to the well established
connection between FGF2 and EMT in a variety of other situations,
including tumor cells (69–72).
Given the role of FGF2 in heparanase-mediated EMT, it may
be discovered that Sulfs also have roles in regulating EMT due to
their interactions with this growth factor. In support of this, there
is a recent finding that suppression of Sulf1, among other proteins,
was associated with activation of EMT in HCC cells via increased
signaling through the Akt and ERK pathways, which would be
expected after Sulf1-mediated FGF2 inhibition was alleviated (73).
CLINICAL ASSOCIATION STUDIES
Reports identifying an association of heparanase, Sulf1, and/or
Sulf2 expression or protein levels from clinical samples have been
discussed in extensive detail in many excellent reviews (7, 8, 66,
74–76). Nevertheless, Table 1 highlights several recent studies,
which have identified an association of these degrading extra-
cellular enzymes of HS with tumor progression, metastasis, and
poor prognosis, and illustrates some of the scientific and clinical
findings in a variety of cancer types.
It has been postulated that heparanase and HSPGs act syn-
ergistically within the tumor microenvironment to enhance
tumor growth and the enzymatic versus non-enzymatic roles
of heparanase in cancer have been discussed elsewhere (74).
Although the active form of heparanase has been identified as
a key player in multiple myeloma (52) and sarcoma (77), several
other studies have linked the overexpression of the active form
with aggressive primary tumor growth, invasion, and metastasis
in certain cancer types. In contrast, Sulf1 has been found to be
downregulated in a number of cancer types while Sulf2 is typ-
ically overexpressed in carcinomas but importantly, these may
be differentially expressed depending on the stage of cancer and
the level of hypoxia in the tumor microenvironment (7). This
section highlights some of the prevalent cancer types, which have
reported significant alterations in heparanase, Sulf1, and/or Sulf2
and how these changes in expression correlate with indices of can-
cer progression such as prognostic indicators, tumor development,
metastasis, and survival.
SOLID TUMORS
PANCREATIC CANCER
Overexpression of heparanase in pancreatic adenocarcinomas
(PDAC) was identified several years ago when investigators discov-
ered that this may facilitate cancer cell invasion and enhancement
of metastatic dissemination (95). Postoperative survival corre-
lated inversely with heparanase expression by tumors reflected
by a median survival of 34 and 17 month for heparanase neg-
ative and positive tumors, respectively (96). Using RT-PCR and
Western Blotting techniques, Chen and colleagues demonstrated
that the expression of HPSE was significantly associated with TNM
grade and invasion to nerves or lymph nodes although did not
reveal a significant difference between histological differentiation
and the tumor size (97). Even serum heparanase was found to be
significantly elevated in PDAC patients (especially in those with
heparanase positive tumors by IHC) and treatment with a small
cohort of patients (n= 11) reduced heparanase levels by 64%
after 2 weeks of treatment with gemcitabine (98). More recently,
pancreatic neuroendocrine tumors (PNET) have now also been
identified as a cancer type in which positive heparanase expression
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Table 1 | Association of heparanase, Sulf1, and Sulf2 in solid tumors and hematologic malignancies.
Enzyme Cancer Key scientific finding Key clinical finding Reference
Heparanase PNET HPSE mRNA ↑ by 40-fold in primary
tumors and metastatic tumors compared
to normal islets
HPSE mRNA was significantly upregulated in PNET
patients with primary tumors (*P =0.046, n=25) and
liver metastases (*P =0.026, n=15) compared to
normal islet samples from normal islets (n=4)
(78)
Heparanase OMM HPSE staining was positive in 81% of
tumors (66 of 81 patients)
Median survival time and 5-year survival rate were
12 months and 7.0% in the high-HPSE group,
35 months and 36.4% in the low-HPSE group,
62 months and 53.3% in the no-HPSE group (P =0.001)
(79)
Heparanase Cervical HPSE ↑ by 63% (38/60) patients by IHC Significant correlation with tumor size and clinical stage (80)
Heparanase Ovarian Median HPSE serum levels 2.77, 4.86 and
7.68 ng/mL in control, benign and
malignant samples respectively
Increased serum HPSE in ovarian cancer patients with
distant metastasis (P <0.05)
HPSE (in conjunction with Cathepsin L and MMP-9)
elevation possibly useful in determining extent of
metastasis before surgery
(81)
Heparanase Oral SCC HPSE ↑ in 41% (19/46) Rate of HPSE expression closely related to tumor size,
tumor stage, lymphatic metastasis, distant metastasis,
pathological and histological stage
(82)
Heparanase Lung* Adenocarcinomas exhibited strong HPSE
expression by IHC
Heparanase expression tended to correlate with tumor
node metastasis (TNM) staging in non-small cell lung
carcinoma
(83)
Heparanase CCC HPSE expression from 47 patient samples
was significantly associated with PDGFRα
expression but not its ligand PDGF
HPSE expression (mRNA) <35th percentile led to
median OS 10.2 months versus HPSE >35th percentile
lead to median OS 20.1 months
(84)
Heparanase HNSCC Strong HPSE expression was localized at
the invasion front of the tumor and in
disseminated tumor cells
Patients lacking HPSE-expressing cells (<5%) in their
tumors had a prolonged DFS of 25.8 compared with
patients with HPSE-positive tumors (>5%) with mean
DFS of 8.2 months. HPSE also higher in lymph nodes
(85)
Cellular HPSE expression was detected in
41 of 71 (58%) cases; in particular, UICC
IV-stage tumors
Patients with high-level HPSE expression had prolonged
overall survival (P =0.029) and this was associated with
low tumor cell proliferation which might outweigh
HPSE-induced invasion and migration in late-stage
tumors
(86)
Heparanase Ewing’s sarcoma 49% (34/69) Of the cases were scored as
low (+1) intensity while 51% (35/69)
exhibited a strong (+2) staining intensity
HPSE staining was evident in all biopsies examined,
exhibiting a high (+2) staining extent (i.e., >50% of the
cells) in the majority (91%) of cases. Possible association
to tumor size (P =0.07), strong staining in 75% of those
with large tumors (>10 cm)
(77)
STS High-HPSE expression in 29 (52.7%)
primary tumors and 22 specimens (47.8%)
in metastatic sites
HPSE expression not correlative with tumor
aggressiveness, tumor recurrence or survival
(87)
Heparanase AML mRNA and/or protein expression of HPSE
revealed low HPSE in ALL (and CLL, NHL)
patients and a high expression level in
MM and AML patients, versus healthy
controls
HPSE mRNA expression was significantly increased in
14/15 patient samples and genotype frequency
comparisons revealed a significant association with
rs4364254 [chi2 (2d.f.)=6.226, P =0.044] in AML
patients. HPSE gene mRNA expression was high in AML
patients
(88, 89)
(Continued)
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Table 1 | Continued
Enzyme Cancer Key scientific finding Key clinical finding Reference
Sulf1 Gastric Sulf1 expression ↑ in tumor tissues
(P =0.0002) compared to normal mucosa
Multivariate analysis found Sulf1 is an independent
prognostic (P =0.01) and lymph node metastasis
predictive factor (P =0.0003) in large cohort of patients
(450)
(90)
Sulf1 Gastric Sulf1 protein expression ↓ which is
discordant with mRNA findings
Despite mRNA expression being ↑ in 30% of samples,
protein expression ↓ in 70% (14/20) of tumor samples
(91)
Sulf2 GBM Sulf2 may alter PDGFRα
signaling/activation to promote
tumorigenesis
Sulf2 expression ↑ in proneural subtype of GBM (n=173,
P <0.005) and ↑ using IHC in 28 subtyped GBMs
demonstrated that proneural and mesenchymal subtypes
(92)
Sulf2 MM Sulf2 ↑ in hyperdiploid group but ↓ in
groups of patients with Cyclin D1 or MAF
translocations
Sulf2 expression in primary MM cells linked to poor
prognosis in two independent large cohorts. Sulf2 was
independently predictive for OS (P =0.02)
(93)
Sulf2 OAC/OSCC Sulf2 detected using IHC on 75 OAC
patients and 25 OSCC patients
Majority of OAC and OSCC had Sulf2 staining. For every
10%, ↑ in % tumor cells staining for Sulf2, the HR for
death ↑ by 13% (P =0.03)
(94)
Sulf2 Various Sulf2 increased (P =0.001) compared to
normal mucosa
Significant overexpression in uveal melanoma (=0.03),
lung adenocarcinoma (P =0.04) and colorectal carcinoma
(P =0.001) compared to low grade, low expressed and
colon adenomas respectively
(93)
AML, acute myeloid leukemia; CCC, cholangiocarcinoma; CLL, chronic lymphoblastic leukemia; DFS, disease-free survival; GBM, glioblastoma multiforme; HCC,
hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; OAC, esophageal adenocarci-
noma; OMM, oral mucosal melanoma; OSCC, esophageal squamous cell carcinoma; PNET, pancreatic neuroendocrine tumors; SCC, squamous cell carcinoma; STS,
soft tissue sarcoma.
*37 Patients, there were 14 adenocarcinomas, 13 squamous cell carcinomas, 5 large cell carcinomas, and 5 small cell carcinomas.
was detected in patient tissue samples. Using tissue microarrays
with samples from over 150 PNET patients, staining intensity of
heparanase (by IHC) significantly correlated with tumor stage,
higher tumor grade (as defined by tumor mitotic activity), and
presence of distant metastasis (78).
Given the increasing understanding of the HS-binding pro-
tein interactome in pancreatic disease, enzymes involved in the
degradation of proteoglycans such as HS may well play partic-
ularly important roles in neoplastic transformation of pancre-
atic cells. Although Sulf1 inhibits angiogenesis and tumorigen-
esis in vivo (30), a number of clinical studies have found that
higher Sulf1 mRNA levels have been associated with tumor tis-
sue compared to normal pancreas in relatively small cohorts of
PDAC patients (99, 100). The finding that Sulf1 and Sulf2 can
promote canonical Wnt signaling, a well described cascade in
PDAC, suggests their overexpression is a contributory factor in
relation to the growth and tumorigenicity of these pancreatic
tumor cells (101). This appears to be in contrast to evidence
that Sulfs block other pro-tumorigenic signaling pathways such
as angiogenesis (29, 30, 33, 100), thus blocking tumor progres-
sion. However, the ability of Sulf1 to potentiate autocrine Wnt
signaling in pancreatic cancer cells appears to be the key factor for
tumors driven by this canonical signaling pathway (101). Taken
together, heparanase, Sulf1, and Sulf2 are enzymes which appear,
at least in pancreatic cancer, to be positive regulators of tumor
development.
HEPATOCELLULAR CARCINOMA
In patients undergoing hepatic resection, expression of heparanase
mRNA was detected in 47% of HCCs and was significantly cor-
related with larger tumor size, presence of portal vein invasion,
higher overall tumor invasiveness, and tumor microvessel density
(MVD). Also, there was a direct correlation between the level of
FGF2 protein and MVD in HCC tissue suggesting that heparanase
enhances growth, invasion, and angiogenesis while FGF2 is a
potent angiogenic factor for HCC (102). Interestingly, Sulf2 is
known to increase FGF2 binding to HCC cells and upregulation
of Sulf2 correlates with a worse prognosis in HCC patients (37).
Chen and colleagues subsequently found a similar positive rate
of increased expression of heparanase mRNA (48.5%) in HCC
tumors compared to surrounding parenchymal tissue. However,
the positive rate increased to 71.4% in patients with a higher ten-
dency of metastasis or recurrence compared with 31.6% in the
group with a low tendency of metastasis or recurrence. The positive
rate for mRNA heparanase in patients with metastasis/recurrence
during postoperative follow-up (78.6%, 11/14) was also signif-
icantly higher than that in those without metastatic recurrence
(21.4%, 3/14), indicating heparanase may be one of the reliable
markers for metastatic activity in HCC (103). A follow-up study
revealed heparanase expression was increased in patients with
metastasis and was dependent on tumor staging with expression
levels lower in clinical TNM stages I and II than in III and IV (104).
Serum heparanase levels have also been reported to be higher in
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patients with large tumors (>5 cm), advanced pTNM stage (III
and IV), tumor capsule absence, and portal vein invasion (105).
Although Sulf2 is purported to exhibit an oncogenic effect in
HCC (37), in contrast, Sulf1 has been identified as having a tumor
suppressor effect in HCC (32, 106). However, in HCC tumor tissue,
expression of Sulf1 is higher compared to adjacent benign tissues
and approximately a third of HCCs express Sulf1 at high levels
>1.5× the level in adjacent benign tissue (107). Moreover, nearly
40% of patients with high tumor Sulf1 expression have the hepato-
blast phenotype of HCC, which has relatively poor survival (108)
and those with mid Sulf1 expression had a better survival out-
come possibly due to the complex interaction of Sulf1 with anti-
and pro-tumorigenic signaling molecules, indicating a bimodal
effect in HCC (107). In contrast, elevated Sulf2 is associated with
a worse prognosis and a unimodal effect in HCC, causing activa-
tion of both tyrosine kinase and Wnt pathways (107). A different
study also reported increased expression of Sulf2 in liver cancer
specimens compared to normal tissue counterparts (93).
GASTRIC CANCERS
Rates of positive expression for heparanase mRNA in gastric can-
cer tissues (31/63, 49%) compared with adjacent normal tissue
(11/42, 26%) was first reported by Endo and colleagues in 2001
(109). A follow-up study confirmed 79.5% (35/44) positive expres-
sion in heparanase protein using immunohistochemistry and also
reported significantly poorer prognosis than those without such
expression (110). A number of subsequent studies confirmed the
increase expression of mRNA or protein in gastric cancer cor-
related with invasion, metastasis, and/or poor survival outcomes
(103, 111–115).
Higher expression of Sulf1 and Sulf2 compared to normal
mucosa has been reported in gastric cancer, with the expression
of Sulf1 significantly correlated with higher recurrence rates and
worse overall survival in patients. Multivariate analysis revealed
that Sulf1 is an independent prognostic factor and lymph node
metastasis predictive factor in these patients (90). However, Sulf1
protein expression has also been reported as being down regu-
lated in gastric cancer tissues, which is discordant with mRNA
overexpression in tumors previously reported by the same labora-
tory (91), thus, demonstrating the complexity in associating Sulf
expression/activity with clinicopathological settings. Laboratory
data reports would suggest that Sulf1 inhibits cell proliferation and
invasion in human gastric cells (116) and suppresses cell growth
while down regulating the pro-tumorigenic Hedgehog signaling
pathway in these cells (117).
HEAD AND NECK CANCERS
Strong heparanase expression in primary tumors and lymph nodes
was initially reported to be associated with prolonged disease-free
progression in head and neck squamous cell carcinoma, HNSCC
(85). Intriguingly, some years later the same group revealed cellular
heparanase expression in late-stage HNSCCs was associated with
prolonged overall survival and proposed that the proliferation-
reducing effect of high heparanase levels might outweigh the
tumor-promoting effects of heparanase in advanced tumors (86).
Despite raising the importance of tumor type, stage, and role of
heparanase in particular tumor microenvironment, other groups
also found heparanase expression to be linked to poor prognosis.
Heparanase expression is induced in HNSCC and is associated
with tumors larger in size, increased invasiveness, and reduced
patient survival (118). In cancer of the salivary glands, Vlodavsky
and colleagues demonstrated very significant differences between
those with high expressing heparanase tumors and those with low
or no positive staining in terms of overall survival (66). Despite
a lack of studies investigating the possible clinical correlates for
Sulf1 or Sulf2 in HNSCC, there is evidence demonstrating that
Sulf1 re-expression, which diminishes cell surface HSPG sulfation,
interferes with both FGF2 and HGF signaling in SCCHN (33) and
that desulfation of the cell surface HSPG by Sulf1 in SCCHN plays
an important role in the control of tumor development (33).
BREAST AND OVARIAN CANCERS
The role of heparanase and HS in breast cancer has been discussed
comprehensively in a recent review (4) but emerging data con-
tinues to identify heparanase as a prognostic marker for tumor
progression in breast cancer. For example, elevated heparanase
expression was associated with the lymph node status, late clinical
stages, a short overall survival, and a short relapse-free survival
with the highest heparanase levels in breast cancer those with
lymph node metastasis. In addition, the serum heparanase lev-
els of patients with metastatic breast cancer were significantly
higher than primary breast cancer patients (119). By contrast,
Fernandez-Vega and colleagues did not find any significant dif-
ferences between heparanase expression in tumors and healthy
tissue. However,despite no significant difference in non-metastatic
tumors, there was a change in metastatic relative to healthy tissue.
Expression of heparanase determined in tissue arrays by immuno-
histochemistry revealed varying levels of heparanase in different
patients (120). Nevertheless, laboratory studies now implicate
heparanase in an invasive cell phenotype driven by the small
GTPases: Rac1 and RhoA in brain metastatic breast cancer cells.
These actions of heparanase on Rac1 and RhoA are mediated
by GEF-H1, suggesting roles for heparanase in the initial events
of BMBC pathogenesis, for example, cell adhesion, cytoskeletal
dynamics, and cell extravasation, which are independent of its
enzymatic activity (121). The clinical value of using heparanase, as
a prognostic biomarker, in combination with MMP-9 and Cathep-
sin, was reported for determining the extent of ovarian cancer
metastasis before surgery (81).
Both Sulf1 and Sulf2 were shown to be overexpressed at gene
and protein levels in non-metastatic invasive ductal carcinomas
although no significant differences could be detected in metasta-
tic tumors (120). However, a recent review article highlighted
the down regulation of Sulf1 in early stage ovarian tumors and
metastatic breast cancer patients (7) while assessment of Sulf2
using a cohort of breast cancer patients found significant upreg-
ulation in autologous metastatic lesion compared with primary
tumors (122). It is of interest to note that as intimated in the PDAC
setting, the tumor type, the Sulf isoform (Sulf1 and/or Sulf2), and
the predominant pathway (Wnt or FGF2) might result in opposing
effects of Sulf ’s on tumor progression and metastasis (122).
Sulf1 has been shown to be markedly downregulated in ovar-
ian cancer cell lines and 75% of ovarian cancer tumor tissues
(43, 123). In addition, a transcription factor vHNF has been
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shown to suppress Sulf1 expression in clear cell carcinoma (123),
whereas HIF-1 alpha have been shown to suppress Sulf1 transcrip-
tion in breast cancer cell lines (64). A subsequent study showed
that restoration of Sulf1 expression leads to decreased tumor
growth, angiogenesis, and enhanced the efficacy of chemother-
apeutic agents such as cisplatin (124). Tumor suppressive effects
of Sulf1 are predominantly linked to its ability to decrease FGF2,
HB-EGF, amphiregulin signaling in ovarian and breast cancer cells
(30, 64, 101). Decreased 6-O sulfation of heparan sulfate due to
increased Sulf1 activities can also be recapitulated or mimicked by
downregulation of 6-O-sulfotransferases (HS6ST1 and HS6ST2).
More recently, it has been shown that downregulation of HS6ST1
reduced the signaling of HS-binding EGF signaling leading to
reduced expression of FGF 1, IL6, and IL8 (125) in ovarian can-
cer cell lines. These data lend further support to the notion that
decreased 6-O sulfation of HS results in reduced formation of
the receptor-HS-growth factor ternary complex thereby limiting
the effect of extracellular growth factors. Clinically, it has been
shown that Sulf1 expression is associated with increased disease-
free and overall survival in breast cancer (64). Similarly, analysis
of 501 ovarian patients revealed that serous tumors with moderate
to high levels of Sulf1 (127 of 186, 68%) showed a trend toward
improved survival as assessed by Kaplan–Meier survival analysis
and log-rank test (123). These data confirm an in vitro finding
indicating a tumor suppressor role of Sulf1.
NON-SMALL CELL LUNG CANCER
Recent studies have identified the overexpression of heparanase in
non-small cell lung cancer (NSCLC) (83, 126). Widespread Sulf2
protein expression was identified in tumor cells of 10/10 surgical
specimens of human lung squamous carcinomas and knockdown
of Sulf2 was found to reduce the growth of lung cancer cells,
inhibit autocrine Wnt signaling, and inhibit tumor progression
in a mouse model of NSCLC (127). The authors concluded that
not only should Sulf2 be considered as a potential biomarker of
lung cancer but that its inhibition could be achievable via small
molecule or biologic agents and thus should be considered as a
therapeutic target in lung cancer.
OTHER SOLID TUMORS
For further examples of the studies that detail the clinical associa-
tion studies with heparanase, readers are referred to several reviews
(6, 74, 75). Similarly, comprehensive reviews on Sulf1 and Sulf2
provide further details of these enzymes in different cancer types
(8, 76). In addition, an over-representation of Sulf2 gene expres-
sion in skin cancer, colorectal carcinoma, testicular teratoma, and
liver cancer compared to their normal tissue counterpart has been
reported (93). Further investigations revealed that Sulf2 was sig-
nificantly overexpressed in high grade uveal melanoma compared
to low grade and in patients presenting colorectal carcinoma
compared to benign colon adenoma (93).
HEMATOLOGIC TUMORS
MYELOMA
Of particular interest in the field is the role of heparanase in
myeloma because its overexpression in the bone marrow envi-
ronment was associated with a shorter event-free survival of
patients with newly diagnosed myeloma treated with high-dose
chemotherapy and stem cell transplantation (52). Heparanase
enhances osteoclastogenesis and bone loss – a major cause of
morbidity in patient with multiple myeloma – by shifting the
differentiation potential of osteoblast progenitors from osteo-
clastogenesis to adipogenesis possibly via induction of the Wnt
signaling pathway inhibitor DKK1 by both osteoblast progeni-
tors and myeloma cells (128). Such effects on osteoclastogenesis
and bone loss can occur, in part, as the result of a significant
elevation in the expression and secretion of receptor activator of
NF-κB ligand (RANKL) by heparanase-expressing myeloma cells.
Another possible mechanism for the pro-tumorigenic effects of
heparanase in myeloma was recently elucidated in animal models,
which revealed that heparanase enhances myeloma progression
via CXCL10 downregulation (129). In addition to an association
of heparanase with myeloma progression, Bret and colleagues
discovered that Sulf2 expression in primary multiple myeloma
cells were associated with a poor prognosis in two independent
large cohorts of patients. It remained an independent predictor
when considered together with conventional multiple myeloma
prognosis factors (93).
LEUKEMIA
In mononuclear cells derived from various leukemias, heparanase
mRNA was expressed in 14 of 15 acute myeloid leukemia (AML)
samples. In contrast, cells derived from all 33 chronic lymphoblas-
tic leukemia, all 7 non-Hodgkin’s lymphoma, 7 of 8 chronic
myeloid leukemia, and 6 of 8 acute lymphoblastic leukemia
patients showed no detectable expression of the heparanase RNA.
Heparanase protein was detected primarily within the cytoplasm
of AML cells, indicating that the enzyme is produced and stored
within the cytoplasm of myeloid cells, with limited expression on
the cell surface (88). The low heparanase gene expression level in
ALL patients and a high expression level in MM and AML patients
were confirmed in a follow-up study (89). A clear correlation
was found between heparanase mRNA expression level and three
HPSE gene single nucleotide polymorphisms (SNPs – rs4693608,
rs11099592, and rs4364254) among healthy individuals. These
data suggested that certain HPSE gene SNPs contributes to basal
heparanase gene expression and that alterations in this gene are
an important determinant in the pathogenesis of hematological
malignancies (89). Sulf1 gene expression has been noted to be
increased in T prolymphocytic leukemia and AML (93).
THERAPEUTIC OPPORTUNITIES
HEPARANASE INHIBITORS
The development of heparanase inhibitors have been reviewed
elsewhere (75, 130, 131) but Table 2 highlights the drug dis-
covery and development projects initiated in the pursuit of
heparanase inhibition and their current status. PI-88 is a mix-
ture of highly sulfated oligosaccharides derived from Pichia hol-
stii, NRRL Y-2448, which is a non-cleavable structural mimic of
HS (132) and is currently progressing through clinical devel-
opment as a dual anti-angiogenic and anti-metastatic agent. As
such, it is known to inhibit angiogenesis by interfering with HS
recognition by many angiogenic growth factors such as VEGF,
FGF1, FGF2, in addition to inhibiting heparanase activity (133).
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Table 2 | Past and present drug discovery/development programs targeting heparanase in oncology.
Company Compound Development stage ClinicalTrials.gov
Identifier/Reference
Medigen Biotechnology Corporation (Taiwan) Muparfostat (PI-88) Phase III (current) NCT01402908
Momenta Pharmaceuticals (US) Necuparanib (M402) Phase I/II (current) NCT01621243
Sigma Tau Pomezia (Italy) Roneparstat (SST0001) Phase I (current) NCT01764880
Progen Pharmaceuticals (Aus) PG545 from PG500 series Phase I (current) NCT02042781
Oxford Glycosciences (UK) OGT2115 Preclinical (discontinued) (131)
Imclone Systems (US) Compound 7a Preclinical (discontinued) (138)
InSight Biopharmaceuticals (Israel) Compound 4 Preclinical (discontinued) (139)
Compounds 1, 6 (140)
Compound 2 (141)
Compound 3 (142)
Astra Zeneca (UK) Antibodies Late discovery (discontinued) (143)
Endotis Pharma (France) EP80061 from EP-8000 series Discovery/preclinical (discontinued) (14, 144)
Unknown (Shanghai Institute of Materia Medica, China) JG3 (oligomannurarate sulfate) Early preclinical (145, 146)
RIKEN Discovery Research Institute (Japan) RK-682 Discovery (147)
KI-105 Discovery (148)
Notably, PI-88 has been shown to inhibit primary tumor growth of
invasive rat mammary adenocarcinoma, metastasis, and reduced
vascularity of these tumors (134) while demonstrating signifi-
cant anti-tumor activity in the pancreatic neuroendocrine RIP2-
Tag2 model (135) and in models of leukemia (136). As the
most advanced heparanase inhibitor, it is currently being tri-
aled in a Phase III study as an adjuvant treatment for patients
with hepatitis virus related hepatocellular carcinoma after surgical
resection (137).
Heparan sulfate mimetics or glycol-split heparins are con-
sidered the most common therapeutic approach to create novel
oncology agents with some others currently in early stage clinical
development. PG545 is a synthetic, potent competitive inhibitor of
heparanase (149) demonstrated to possess significant anti-tumor,
anti-angiogenic, and anti-metastatic activity in a variety of ani-
mal models (150–152). This agent is currently being assessed in a
Phase I trial for patients with advanced solid tumors (153). M402
is a rationally engineered, non-cytotoxic HS mimetic, designed
to inhibit multiple factors implicated in tumor–host cell interac-
tions, including VEGF, FGF2, SDF1α, P-selectin, and heparanase
demonstrating anti-metastatic activity alone and in combination
with cisplatin or docetaxel in the orthotropic 4T1 murine mam-
mary carcinoma model (154). Necuparanib (M402) is current
under investigation with nab-paclitaxel and gemcitabine in pan-
creatic cancer (155). Roneparstat (SST0001) is an N -acetylated,
glycol-split heparin, which inhibits heparanase, downregulates
HGF, VEGF, and MMP-9 expression and suppresses angiogene-
sis. Roneparstat also diminishes heparanase-induced shedding of
syndecan-1, which is known to be a potent promoter of myeloma
growth (156). Roneparstat is currently being tested in a Phase I
trial for patients with advanced multiple myeloma (157). Oligom-
manurarate sulfate (JG3), a novel marine-derived oligosaccha-
ride, was also reported as a heparanase inhibitor (145), but has
yet to be progressed to the clinic (as defined by registration on
www.clinicaltrials.gov).
Apart from HS mimetics, small molecule inhibitors, and neu-
tralizing antibody programs were developed by various compa-
nies including Oxford Glycosciences (158, 159), Imclone Systems
(138, 160), and InSight Biopharmaceuticals (139–142), but the
candidates failed to reach clinical trials. Although the reasons
for the limited progression through to clinical development are
unknown, the lack of a crystal structure for the heparanase pro-
tein may have been one of the confounding issues. But, it is
interesting to note that the induction of endoplasmic reticulum
stress by chemotherapeutic reagents is involved in the enhanced
invasion and migration ability of breast cancer cells and inhi-
bition of heparanase (using one of these inhibitors, OGT2115)
suppressed the invasion and migration ability of breast cancer
cells. This provides a strong rationale for the development of
heparanase-based therapeutics for the prevention of metastasis
induced by chemotherapeutic reagents (161). The use of OGT2115
combined with cisplatin led to significant inhibition of cell prolif-
eration, invasion, and migration of human nasopharyngeal cells,
further suggesting that combination approaches with heparanase
inhibitors may improve outcomes with existing chemotherapeutic
regimens (162).
Recent discovery stage reports have identified new puta-
tive heparanase inhibitors but these continue to be classified
www.frontiersin.org July 2014 | Volume 4 | Article 195 | 9
Hammond et al. Heparanase and sulfatases in tumors
as heparin derivatives or HS mimetics. TD4-143-1, which is a
selectively sulfated tetrasaccharide containing unsubstituted glu-
cosamine residues, which inhibited heparanase activity and sup-
pressed invasion of breast cancer cells in vitro (163). Although not
designed to specifically inhibit just heparanase, a newly synthe-
sized hexasaccharide was considered to possess typical heparanase
inhibition profile consistent with LMWHs and fondapariunx
(164). Nevertheless, in both instances the anti-heparanase activ-
ity would be considered to be modest which perhaps limits
the utility of such approaches in terms of preclinical or clinical
development.
SULFATASE MODULATORS
In considering Sulf1 or Sulf2 as drug targets, the main considera-
tion is the increasing evidence implicating the Sulfs in cancer and
whether these are responsible for augmenting cancer cell growth
or inhibiting it (31, 32, 37, 101, 165). The HS mimetic PI-88 was
demonstrated to inhibit the Sulfs with IC50 values in the range of
1.2–2.6µg/mL, which is comparable to that of heparanase (166).
Although not specific for the Sulfs, the study suggested that inhibit-
ing the Sulfs should be linked to an anti-tumor effect. However, it
has been recently demonstrated that the loss of Sulf1 expression
promotes tumorigenicity in ovarian cancer cells through regulat-
ing Bim expression (42). In gastric cancer cells, expression of Sulf1
significantly suppressed cellular proliferation possibly through
abrogating the Hedgehog signaling pathway (117). In fact, the
expression of Sulf1 mediated by adenovirus in liver carcinoma cells
downregulates the activity of AKT and ERK signaling pathways,
and inhibits HCC cell migration and proliferation, which makes it
a candidate anti-tumor factor for cancer gene therapy (167). These
data are corroborated by another recent study using microRNA
miR-21 which suppressed Sulf1 and enhanced the activity of liver
carcinoma cell proliferation and xenograft tumor growth in mouse
models (73).
Conversely, silencing of Sulf2 expression in breast cancer cells
attenuated ductal carcinoma in situ progression to invasive ductal
carcinoma in vivo (168). Moreover, proteasomal inhibitors such as
bortezomib abolished Sulf2 expression in multiple breast cancer
cells (122). Consistent with these studies, a disulfonyl derivative
of phenyl–tert–butyl nitrone (PBN) called OKN-007 was shown
to inhibit Sulf2 activities in hepatocellular carcinoma cell lines
although its activity against Sulf1 has not been assessed. OKN-
007 effectively inhibited tumor growth in HCC derived tumor
xenografts exhibiting Sulf2 expression (169). Taken together, these
studies suggest that while inhibiting Sulf2 may exert anti-tumor
activities, the modulation of Sulf1 may have a divergent impact
on tumor progression and be highly dependent on the tumor
type and the key signaling pathways (e.g., Wnt) characterized to
promote cell proliferation and survival in these tumors. Thus,
significant inroads need to be made in researching the Sulfs
as an appropriate target in cancer and identifying the optimal
approaches needed to modulate their expression and activity
in cancer.
CONCLUSION
The modification of HSPG in the tumor microenvironment mod-
ulates a variety of processes that are important in cancer growth
and spread. Three enzymes – heparanase, Sulf1 and Sulf2 – play
crucial roles in regulating HSPG functioning in this compart-
ment and the up- and down-regulation of these proteins in a
large variety of cancers demonstrates how important they are
in promoting or repressing malignancy. While the involvement
of heparanase in progressing tumors is well-documented, both
at the mechanistic level and in clinical observations, the roles
of the Sulfs are not so clear, particularly for Sulf1. This clarity
is reflected in the more advanced stage of clinical development
that anti-heparanase therapeutics has reached in comparison to
Sulf inhibitors. Resolution of the pro- and anti-tumor properties
of the Sulfs and how these relate to tumor-stromal relationships,
primary and metastatic lesion interactions, and other aspects of
tumor growth is required before the development of anti-Sulf
therapeutics can proceed with confidence. Nevertheless, there is a
substantial body of data describing the importance of heparanase,
Sulf1, and Sulf2 in modulating HS functioning in cancer, which
highlights the already well founded view that targeting the ability
of tumors to modify their microenvironment in order to promote
growth and spread represents a solid therapeutic development
pathway.
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